Indiana University (IU) School of Medicine and Eli Lilly have come together to transform how university research and pharmaceutical companies do business. Why? Because at the end of the day, it’s all about the patient. This requires organizations to make a “leap of faith” and be open to a new kind of value creation. This comes with a new $5 million partnership that’s certainly going to get some attention. What traditionally got in the way of deeper university and pharmaceutical companies ties, intellectual property, won’t be a hindrance anymore.
Focus Autoimmune Disease
With a focus on autoimmune diseases, the new research partnership will look into rheumatoid arthritis, inflammatory bowel disease and Crohn’s disease. This partnership will also include the Indiana Clinical and Translational Sciences Institute (CTSI), with a well known brand associated with its research analytics. By also including the Regenstrief Institute, known nationwide for its digital health data endeavors, the partnership combines Lilly’s deep and rich data with IU’s analytics and informatics ability for something exciting and new in the world of immunology research reports Kylie Veleta writing for Inside Indiana Business.
This innovative new partnership will tap into Lilly’s rich pipeline of potential molecules which represent the building blocks or new drugs in the targeted segments of autoimmune and immunology. Moreover, the partnership will leverage the Indianapolis-based company’s deep supply of de-identified genomic data.
Professor of Medicine Dr. Andrew Dahlem reports that Lilly, “has an amazing pipeline” of possible molecules that the teams can jointly capitalize on.
Andrew Dahlem, MD, Senior Research Professor, Medicine
Call to Action: Follow the link to read the rest of the report on this important new partnership.